Insider · CIK 0001916764
Patricia A. Martin
Files at CYPH (CYPHERPUNK TECHNOLOGIES INC.), ANTX (AN2 Therapeutics, Inc.). First filing Sep 25, 2026, latest Sep 25, 2026.
In brief
Patricia A. Martin files SEC Form 4 as director at CYPH (CYPHERPUNK TECHNOLOGIES INC.), and also at ANTX (AN2 Therapeutics, Inc.). Since Sep 25, 2026, Patricia A. Martin has reported 0 open-market buys worth $0 and 1 open-market sell worth $193k, the latest filed on Sep 25, 2026.
A track record needs three past buys with six months of prices behind them; Patricia A. Martin has 0, so none is measured yet.
The newest scored trade: sold $193k of CYPH on Sep 23, 2026, filed Sep 25, 2026, scored 45 (moderate). In the last 12 months: 0 buys worth $0 and 1 sell worth $193k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CYPH: CYPHERPUNK TECHNOLOGIES INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | CYPHERPUNK TECHNOLOGIES INC. | $193k 50,000 shares | -30% | - |
Transactions
Every row this insider has filed, 23 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 23, 2026 | CYPH CYPHERPUNK TECHNOLOGIES INC. | SOpen-market sale Common Stock | -50,000 | $3.86 | $193k | 118,750 | 18 d ago |
| Jul 10, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Common Stock | +766 | $0.00 | $0 | 18,863 | Jul 10, 2026 |
| Jul 1, 2026 | CYPH CYPHERPUNK TECHNOLOGIES INC. | AGrant or award Restricted Stock Unitsderivative | -75,000 | $0.00 | $0 | 75,000 | Jul 2, 2026 |
| Apr 10, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Common Stock | +1,192 | $0.00 | $0 | 18,097 | Apr 10, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +24,999 | - | - | 24,999 | Mar 23, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -24,999 | - | - | 0 | Mar 23, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +10,362 | - | - | 10,362 | Mar 23, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -10,362 | - | - | 0 | Mar 23, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +23,742 | - | - | 23,742 | Mar 23, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -23,742 | - | - | 0 | Mar 23, 2026 |
| Mar 13, 2026 | CYPH CYPHERPUNK TECHNOLOGIES INC. | MOption exercise Common Stock | +74,700 | - | - | 74,700 | Mar 17, 2026 |
| Mar 13, 2026 | CYPH CYPHERPUNK TECHNOLOGIES INC. | MOption exercise Common Stock | +94,050 | - | - | 168,750 | Mar 17, 2026 |
| Mar 13, 2026 | CYPH CYPHERPUNK TECHNOLOGIES INC. | MOption exercise Restricted Stock Unitsderivative | -74,700 | $0.00 | $0 | 0 | Mar 17, 2026 |
| Mar 13, 2026 | CYPH CYPHERPUNK TECHNOLOGIES INC. | MOption exercise Restricted Stock Unitsderivative | -94,050 | $0.00 | $0 | 0 | Mar 17, 2026 |
| Feb 20, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +20,400 | $0.00 | $0 | 20,400 | Feb 23, 2026 |
| Jan 12, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Common Stock | +3,650 | $0.00 | $0 | 16,905 | Jan 14, 2026 |
| Dec 23, 2025 | CYPH CYPHERPUNK TECHNOLOGIES INC. | AGrant or award Restricted Stock Unitsderivative | +94,050 | $0.00 | $0 | 94,050 | Dec 30, 2025 |
| Nov 11, 2025 | CYPH CYPHERPUNK TECHNOLOGIES INC. | AGrant or award Restricted Stock Unitsderivative | +74,700 | $0.00 | $0 | 74,700 | Nov 13, 2025 |
| Oct 10, 2025 | ANTX AN2 Therapeutics, Inc. | AGrant or award Common Stock | +3,274 | $0.00 | $0 | 13,255 | Oct 14, 2025 |
| Jul 10, 2025 | ANTX AN2 Therapeutics, Inc. | AGrant or award Common Stock | +3,750 | $0.00 | $0 | 9,981 | Jul 11, 2025 |
| May 22, 2025 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +19,111 | $0.00 | $0 | 19,111 | May 23, 2025 |
| Apr 10, 2025 | ANTX AN2 Therapeutics, Inc. | AGrant or award Common Stock | +3,065 | $0.00 | $0 | 6,231 | Apr 11, 2025 |
| Dec 19, 2024 | ANTX AN2 Therapeutics, Inc. | AGrant or award Common Stock | +3,166 | $0.00 | $0 | 3,166 | Dec 23, 2024 |
Questions about Patricia A. Martin
Answered from the filings on this page, as of the latest one.
Is Patricia A. Martin buying or selling?
In the last 12 months Patricia A. Martin reported 0 open-market buys worth $0 and 1 open-market sell worth $193k on SEC Form 4; the latest was sold $193k of CYPH on Sep 23, 2026. Grants, option exercises and tax withholding are not counted.
How did Patricia A. Martin's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Patricia A. Martin has 0.
Where does Patricia A. Martin file Form 4?
Patricia A. Martin has filed Form 4 at CYPH (CYPHERPUNK TECHNOLOGIES INC.); ANTX (AN2 Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.